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Targeting ErbB-2 nuclear localization and function inhibits
breast cancer growth and overcomes trastuzumab resistance
RI Cordo Russo1,4, W Béguelin1,4, MC Díaz Flaqué1, CJ Proietti1, L Venturutti1, N Galigniana1, M Tkach1, P Guzmán2, JC Roa2, NA O'Brien3,
EH Charreau1, R Schillaci1 and PV Elizalde1
Membrane overexpression of ErbB-2/HER2 receptor tyrosine kinase (membrane ErbB-2 (MErbB-2)) has a critical role in breast cancer
(BC). We and others have also shown the role of nuclear ErbB-2 (NErbB-2) in BC, whose presence we identified as a poor prognostic
factor in MErbB-2-positive tumors. Current anti-ErbB-2 therapies, as with the antibody trastuzumab (Ttzm), target only MErbB-2.
Here, we found that blockade of NErbB-2 action abrogates growth of BC cells, sensitive and resistant to Ttzm, in a scenario in which
ErbB-2, ErbB-3 and Akt are phosphorylated, and ErbB-2/ErbB-3 dimers are formed. Also, inhibition of NErbB-2 presence suppresses
growth of a preclinical BC model resistant to Ttzm. We showed that at the cyclin D1 promoter, ErbB-2 assembles a transcriptional
complex with Stat3 (signal transducer and activator of transcription 3) and ErbB-3, another member of the ErbB family, which
reveals the first nuclear function of ErbB-2/ErbB-3 dimer. We identified NErbB-2 as the major proliferation driver in Ttzm-resistant
BC, and demonstrated that Ttzm inability to disrupt the Stat3/ErbB-2/ErbB-3 complex underlies its failure to inhibit growth.
Furthermore, our results in the clinic revealed that nuclear interaction between ErbB-2 and Stat3 correlates with poor overall
survival in primary breast tumors. Our findings challenge the paradigm of anti-ErbB-2 drug design and highlight NErbB-2 as a novel
target to overcome Ttzm resistance.
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INTRODUCTION
ErbB-2, a member of the ErbB family of receptor tyrosine (Tyr)
kinases (EGF-R/ErbB-1, ErbB-2, ErbB-3 and ErbB-4), is a major player
in the breast cancer (BC) scenario. Membrane ErbB-2 (MErbB-2)
overexpression or gene amplification in human BC are associated
with increased metastatic potential and poor prognosis.1–3 ErbB
ligands include all isoforms of heregulins (HRGs), which bind to
ErbB-3 and ErbB-4, and recognize EGF-R and ErbB-2 as
coreceptors.4 Upon HRG binding, ErbBs form homo- and hetero-
dimers. This stimulates their Tyr kinase activity and results in the
activation of signaling pathways, the classic transduction mechan-
ism of ErbB’s proliferative effects. Although ErbB-2 is an orphan
receptor, it dimerizes with the other ErbBs. In BC cells over-
expressing MErbB-2, it also assembles homo- and heterodimers in
the absence of ligand.5,6 Membrane ErbB-3 (MErbB-3) critical role
as ErbB-2 coreceptor mediating ligand-independent and HRG-
induced ErbB-2 signaling and growth effects in BC has been
proved in several works, including ours.7–13 Also, MErbB-3
overexpression is a prognosis of poor BC survival.14,15
Current therapeutic options for patients whose tumors over-
express MErbB-2 (ErbB-2-positive BC subtype) include monoclonal
antibodies (trastuzumab (Ttzm) and pertuzumab), Tyr kinase
inhibitors (lapatinib) and trastuzumab-DM1, an antibody–drug
conjugate. Despite a significant clinical response to Ttzm, the first
anti-ErbB-2 therapy approved for metastatic and early-stage
BC,16,17 around 40 to 60% of patients with MErbB-2-
overexpressing metastatic BC do not respond to Ttzm, showing
either de novo or acquired resistance.16,18
A major contribution to the understanding of the ErbB-2
biology was the demonstration that MErbB-2 migrates to the
nucleus (nuclear ErbB-2 (NErbB-2)), where it acts as a transcription
factor.19 We showed that in BC cells stimulated with progestin,
ErbB-2 assembles a transcriptional complex in which it functions
as a coactivator of the signal transducer and activator of
transcription 3 (Stat3), another key regulator in BC, to promote
the expression of cyclin D1 and induce growth.20 The nuclear
presence of several HRG isoforms as well as of ErbB-3 was
detected in BC cells and primary tumors.6,21–24 However, HRG and
ErbB-3 nuclear function in BC remains poorly known.
Here, we explored basal and HRG-modulated nuclear interaction
and function of ErbB-2 and ErbB-3 and their role in proliferation and
response to Ttzm in ErbB-2-positive BC. We revealed the first
nuclear function of the ErbB-2/ErbB-3 dimer. Our findings showed
that NErbB-2 is the major driver of growth in Ttzm-resistant BC, and
demonstrated that blockade of NErbB-2 localization is a novel
therapeutic strategy to overcome Ttzm resistance.
RESULTS
Nuclear ErbB-2 drives HRGβ1-induced BC growth
We previously found that inhibition of NErbB-2 presence blocks
progestin-induced growth of the ErbB-2- and ErbB-3-
overexpressing C4HD murine BC model.20 To block NErbB-2
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presence, we transfected cells with a human ErbB-2 nuclear
localization domain mutant (hErbB-2ΔNLS), unable to translocate
to the nucleus,25 and which functions as a dominant-negative
(DN) inhibitor of endogenous ErbB-2 nuclear migration.20 Here, we
found that HRGβ1 induced ErbB-2 nuclear localization in C4HD
cells (Supplementary Figure S1a). hErbB-2ΔNLS acts as DN
inhibitor of endogenous ErbB-2 nuclear translocation, retains its
intrinsic Tyr kinase activity and functions as an upstream activator
of Stat3 phosphorylation in C4HD cells treated with HRGβ1
(Supplementary Figures S1b and c). ErbB-2 silencing abrogated
HRGβ1 proliferative effects, which were restored when we
re-expressed wild-type human ErbB-2 (ErbB-2-WT), but not
hErbB-2ΔNLS (Figure 1a). Transfection of hErbB-2-ΔNLS into cells
retaining their endogenous ErbB-2 abrogated the proliferative
response to HRGβ1 (Figure 1a and Supplementary Figure S1d),
consistent with our findings that hErbB-2-ΔNLS is a DN inhibitor of
endogenous ErbB-2 proliferative effects in BC.20 Proliferation
of C4HD cells under basal conditions, in which ErbB-2 is not
present at the nucleus,20 was not affected by transfection with
hErbB-2ΔNLS. Next, we developed an in vivo BC model induced by
HRGβ1. C4HD cells transfected with the empty pcDNA3.1 vector
(C4HD) were inoculated subcutaneously into nude mice implanted
with HRGβ1 pellets. While all mice receiving HRGβ1 developed
tumors, no tumors arose in the control group implanted with
bovine serum albumin pellets (Figures 1b and c). Tumors from
mice receiving HRGβ1 were grade III carcinomas with an invasive
growth pattern and with lack of glandular or tubular differentia-
tion (Figure 1b). We also conducted a preclinical study of
inhibition of NErbB-2 presence in this model. Cells transfected
with the hErbB-2ΔNLS (C4HD-hErbB-2ΔNLS) were inoculated into
mice implanted with the HRGβ1 pellets. Only three out of six mice
injected with C4HD-hErbB-2ΔNLS cells developed tumors. Mean
volume and growth rates of C4HD-hErbB-2ΔNLS tumors were
significantly lower than those of C4HD (Figures 1b and c). C4HD-
hErbB-2ΔNLS tumors showed lower histologic grade (II) as
compared with C4HD, their growth pattern was less invasive
and they display glandular differentiation (Figure 1b). Consistent
with our previous in vitro findings with HRGβ1,9,11,12 in C4HD
tumors we observed ErbB-2 phosphorylation at Tyr 1272 (Tyr 1222
in the human protein), an autophosphorylation site, and at Tyr 927
(Tyr 877 in human), a site different from the autophosphorylation
ones and whose phosphorylation we previously detected in
NErbB-2.20 Here, we also found ErbB-3 and Stat3 phosphorylation
in C4HD tumors (Figure 1d). Increased phosphatidylinositol
3-kinase (PI3K)/AKT pathway activation26,27 and presence of
HRGβ1-induced MErbB-2/ErbB-3 dimers28,29 have been found to
cause Ttzm resistance. Interestingly, we detected the same levels
of ErbB-2, ErbB-3, Stat3 and Akt phosphorylation, and of ErbB-2/
ErbB-3 dimers, in C4HD-hErbB-2ΔNLS and C4HD tumors (Figures
1d and e). At the end of the experiment, ~ 36% of the cells
still expressed the green fluorescent protein (GFP)-tagged
hErbB-2ΔNLS mutant (Supplementary Figure S1e). These findings
demonstrate that blockade of ErbB-2 nuclear localization inhibits
in vivo growth of MErbB-2-positive BC in a scenario where HRGβ1
induces ErbB-2 and ErbB-3 phosphorylation and heterodimeriza-
tion and where Akt is highly phosphorylated.
Comparison between hErbB-2ΔNLS and Ttzm effects in ErbB
activation and BC growth
NErbB-2 was already detected in MErbB-2-overexpressing and
Ttzm-sensitive BT-474 and SK-BR-3 cells.19,30–32 Here, we found
that HRGβ1 further stimulated ErbB-2 nuclear migration, which
remained unaffected by Ttzm (Figure 2a). While basal MErbB-2
levels were significantly higher than those of NErbB-2 in both cell
lines, HRGβ1 treatment inverted the ratio of NErbB-2 to MErbB-2 in
SK-BR-3 cells, and increased the levels of NErbB-2 in BT-474 by
80% (Figures 2a and b). Transfection with hErbB-2ΔNLS abrogated
basal and HRGβ1-induced ErbB-2 nuclear translocation (Figure 2c).
Also, hErbB-2ΔNLS induced comparable levels of basal growth
inhibition to those exerted by Ttzm (Figure 2d). The addition of
exogenous ErbB ligands was found to overcome Ttzm antiproli-
ferative effects.31,33,34 Contrastingly, the antiproliferative effects of
hErbB-2ΔNLS were not counteracted by HRGβ1 (Figure 2d).
Constitutive ErbB-2 phosphorylation at Tyr 1222 and Tyr 877 was
found in both lines, which was significantly decreased by HRGβ1
(Figure 2e), as described for Tyr 877.29,31 Ttzm has already been
found to decrease,35 increase27,30,31 or have no effect on ErbB-2
phosphorylation in BC.29 Here, we found that it significantly
stimulates ErbB-2 phosphorylation, which was not modified by its
combination with HRGβ1 (Figure 2e). Transfection with hErbB-
-2ΔNLS did not modify ErbB-2 basal phosphorylation or ErbB-2
phosphorylation induced by HRGβ1 (Figure 2e). It is well acknowl-
edged that HRGβ1 stimulates ErbB-3 phosphorylation, leading to
Akt activation in BC cells,36,37 an effect that is not counteracted by
Ttzm.29,33 Our present findings showed that HRGβ1 effects on
ErbB-3 phosphorylation and Akt activation also remained unaf-
fected by transfection with hErbB-2ΔNLS (Figure 2e). Like in
previous findings in HRG-stimulated and Ttzm-treated cells,29
ErbB-2/ErbB-3 heterodimers were detected in hErbB-2ΔNLS-trans-
fected cells treated with HRGβ1 (Figure 2f). These findings are in
accordance with our in vivo results in the mouse model and reveal
that inhibition of NErbB-2 presence abolishes growth of MErbB-2-
overexpressing human BC cells, in spite of HRGβ1-induced
formation of ErbB-2/ErbB-3 dimers leading to ErbB-3 phosphoryla-
tion and PI3K/AKT pathway activation. Contrastingly, Ttzm is not
capable of abrogating proliferation of either BC cells with increased
PI3K/AKT activation or which display ErbB-2/ErbB-3 dimers formed
upon HRGβ1 stimulation.27,29,34,38
Inhibition of ErbB-2 nuclear localization blocks proliferation in
Ttzm-resistant BC
We examined hErbB-2ΔNLS effects on the proliferation of
intrinsically Ttzm-resistant JIMT-1 human BC cells.39 JIMT-1 cells
show several molecular traits underlying Ttzm resistance, such as
an activating mutation in PIK3CA, the gene that codes for the
p110α catalytic subunit of PI3K, low levels of PTEN and high
content of HRG.40,41 NErbB-2 was readily detected in JIMT-1 cells.
Its levels were significantly higher than those of MErbB-2 and were
enhanced by HRGβ1 (Figures 3a and b). Ttzm did not modify basal
levels of NErbB-2 and was unable to inhibit HRGβ1-induced ErbB-2
nuclear migration (Figure 3a and Supplementary Figure S2a, which
shows quantification of confocal images). On the contrary,
transfection with hErbB-2ΔNLS blocked ErbB-2 nuclear localization
in HRGβ1-treated and -untreated cells (Figure 3a). ErbB-2-
amplified and intrinsic Ttzm-resistant MDA-MB-453 and HCC1569
cells also display basal ratios of MErbB-2/NErbB-2 lower than 1
(Figure 3b displays the quantification of confocal images shown in
Supplementary Figure S2b). As reported,41 MErbB-2 levels in
JIMT-1, MDA-MB-453 and HCC1569 cells were significantly lower
than those in Ttzm-sensitive BT-474 and SK-BR-3 cells (Figure 3c,
confocal images shown in Figure 2a and Supplementary Figure
S2b). Ttzm-resistant HCC1419 cells showed a ratio of MErbB-2/
NErbB-2 higher than 1. However, their basal NErbB-2 expression
was significantly higher than in responsive cells (Figure 3d displays
the quantification of confocal images shown in Supplementary
Figure S2b). Acquisition of Ttzm resistance in BT-474 clones does
not involve changes in MErbB-2 levels,41,42 nor in total Stat3
expression (Supplementary Figure S2c). Here, we found the same
result in a BT-474HR clone we selected for its acquired resistance
to Ttzm42 (Figure 3c, and images in Supplementary Figure S2b),
where, however, we found increased NErbB-2 levels, and
consequently decreased MErbB-2/NErbB-2 ratios as compared
with parental cells (Figures 3b, d and 2b). HRGβ1 increased
NErbB-2 levels in all Ttzm-resistant cells (Figure 3d and
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Figure 1. Nuclear ErbB-2 drives HRGβ1-induced BC growth. (a) Endogenous ErbB-2 expression was silenced by transfection with ErbB-2 siRNAs
and expressions of either hErbB-2WT or hErbB-2ΔNLS were restored by co-transfection with the respective plasmids. Cells were treated with
HRGβ1 and [3H]thymidine incorporation was used as a measure of DNA synthesis. Data are presented as mean± s.d. For b vs a: Po0.001. The
experiment shown is representative of a total of three. (b) Preclinical model of in vivo blockade of ErbB-2 nuclear localization. Left panel: Cells
(106) were inoculated subcutaneously in mice treated with HRGβ1. As control, mice were injected with pcDNA3.1 vector-transfected cells
(C4HD) and treated with bovine serum albumin (BSA). Each point represents the mean tumor volume± s.e.m. Right panel: Decrease in tumor
mass and histopathologic analysis of tumors. Hematoxylin and eosin (H&E) staining of histologic sections from tumors excised at day 40.
Mitoses are indicated with red arrows. (c) Tumor growth. aGrowth rates were calculated as the slopes of growth curves. Volume, percentage of
growth inhibition and delay in tumor growth were calculated at day 40. # vs *: Po0.001. bWith respect to C4HD cells, Po0.001. (d) Tumor
lysates were analyzed by WB. Shown are two representative tumors from each group. C4HD cells not treated with HRGβ1 were used as a
control for the protein phosphorylation state. (e) Tumor lysates were immunoprecipitated (IP) with ErbB-2 and analyzed by WB with ErbB-3
antibodies. Membranes were reprobed with ErbB-2 antibodies. IgG was used as control of specificity. Total lysates from C4HD cells transfected
with the empty pcDNA3.1 vector were blotted in parallel (see Supplementary Figure S1).
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Supplementary Figure S2b). Transfection of hErbB-2ΔNLS inhibited
JIMT-1 cell growth, which was not affected by HRGβ1 (Figure 3e).
This blockade of proliferation occurs in a scenario in which ErbB-2,
ErbB-3 and Akt are phosphorylated, and ErbB-2/ErbB-3 dimers
are formed in both HRGβ1-treated and -nontreated cells
(Figures 3f and g). hErbB-2ΔNLS also functioned as a DN inhibitor
of endogenous ErbB-2 nuclear migration in a panel of Ttzm-
resistant lines (Supplementary Figure S2d), and inhibited basal
and HRGβ1-stimulated growth of these lines (Figure 3h). Next, we
developed a preclinical model where JIMT-1 cells were transfected
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with hErbB-2ΔNLS (JIMT-1-hErbB-2ΔNLS) or pcDNA3.1 (JIMT-1)
and were inoculated into nude mice. When JIMT-1 tumors reached
40mm3, mice were divided into three groups and injected with
Ttzm or immunoglobulin G (IgG), or remained untreated. Only two
out of eight mice injected with JIMT-1-hErbB-2ΔNLS cells
developed tumors. Mean volume and growth rates of JIMT-1-
hErbB-2ΔNLS tumors were significantly lower than those of JIMT-1
(Figures 3i and j). As reported previously,43,44 no significant
differences were observed either in mean volumes or growth rates
between tumors developed from JIMT-1 cells and those from
JIMT-1 cells treated with Ttzm (Figures 3i and j). Our results reveal
that abrogation of NErbB-2 presence is a successful strategy to
block proliferation in Ttzm-resistant BC.
ErbB-2, ErbB-3, Stat3 and HRGβ1 colocalize and physically
associate in the nucleus
We used BC cells devoid of basal NErbB-2 as the simplest model to
explore the mechanism underlying NErbB-2 action and focused on
the nuclear interaction between Stat3 and ErbB-2 we previously
identified.20 As found in C4HD cells (Figures 4a and b and
Supplementary Figure S1), HRGβ1 caused ErbB-2 nuclear transloca-
tion in T47D human BC cells (Figures 4a and b). Full-length ErbB-2
nuclear translocation was shown by the identical molecular mass of
NErbB-2 compared with that of ErbB-2 in total cell extracts,
corresponding to the entire 185 kDa protein (Figure 4a) and was
also shown by our findings with both the ErbB-2 carboxyl- and
amino-terminal antibodies. Comparable also with our results in
C4HD cells (Figure 1a and Supplementary Figure S1d), blockade of
HRGβ1-induced NErbB-2 presence inhibited HRGβ1-stimulated but
not basal T47D cell growth (Supplementary Figure S3a). Taken
together, our findings in C4HD cells overexpressing MErbB-2 and in
T47D cells displaying moderate amounts of MErbB-2 confirm the
specificity of hErbB-2ΔNLS action, which abrogates BC cell
proliferation only when driven by NErbB-2. Inhibition of HRGβ1-
induced ErbB-2 phosphorylation with the kinase inhibitor AG825
(Supplementary Figure S3b) blocked ErbB-2 nuclear migration
(Figures 4a and b). HRGβ1 also stimulated Stat3 nuclear trans-
location (Figures 4a and b). Stat3 tyrosine phosphorylation is
mandatory for its nuclear migration.45,46 Consistently, preincubation
with AG825, which we found prevents HRGβ1/ErbB-2-stimulated
Stat3 phosphorylation,11 abolished Stat3 nuclear localization
(Figures 4a and b). HRGβ1 stimulated nuclear colocalization and
physical association of ErbB-2 with Stat3 (Figures 4b and c). HRGβ1
also caused ErbB-3 nuclear migration, where it is phosphorylated at
Tyr 1289 (Figures 4a and d). Inhibition of ErbB-2 phosphorylation
with AG825, which abrogates ErbB-2-mediated ErbB-3 tyrosine
phosphorylation,8,47 prevented ErbB-3 nuclear translocation, reveal-
ing that ErbB-3 phosphorylation is required for its nuclear migration
(Figure 4a). ErbB-3 colocalizes with ErbB-2 at the membrane in the
absence of HRGβ1 (Figure 4d). Here we found that HRGβ1 induces
nuclear colocalization of ErbB-2 and ErbB-3 (Figure 4d). HRGβ1 itself
translocates to the nucleus where it colocalizes with ErbB-2
(Figure 4e). We also found physical association among ErbB-2,
ErbB-3 and HRGβ1 in the nucleus, and between Stat3 and ErbB-3
(Figure 4f). These findings reveal that HRGβ1 induces the formation
of nuclear ErbB-2/ErbB-3 dimers, to which HRGβ1 remains bound,
and which assemble a multimeric protein complex with Stat3 in BC
cells. Basal nuclear Stat3 (NStat3) and ErbB-3 (NErbB-3), as well as
ErbB-2/Stat3 and ErbB-2/ErbB-3 colocalization, were found in
BT-474 and JIMT-1 cells (Figures 4g and h), where HRGβ1 further
stimulated migration and colocalization of said proteins. Basal levels
of NStat3 and NErbB-3 and their colocalization with NErbB-2 were
significantly higher in JIMT-1 than in BT-474 cells (Figures 4g and h).
Contrastingly, the majority of ErbB-2/ErbB-3 dimers were localized
at the cytoplasmic membrane in BT-474 cells (Figure 4h). Our
studies of hErbB-2ΔNLS actions showed that it colocalized with
ErbB-3 at the membrane and at the cytoplasm, and abrogated
HRGβ1-induced ErbB-3 nuclear translocation (Figure 4i). Ttzm failed
to block basal and HRGβ1-induced ErbB-2 and Stat3 nuclear
translocation, and consequently ErbB-2/Stat3 nuclear colocalization
in BT-474 and JIMT-1 cells (Supplementary Figure S3c).
HRGβ1 induces the assembly of a Stat3/ErbB-2/ErbB-3
transcriptional complex at the cyclin D1 promoter in both
Ttzm-sensitive and -resistant BC cells
We previously found that in BC, progestin induces the assembly of
a Stat3/ErbB-2 transcriptional complex at the Stat3-response
elements (GAS) of the cyclin D1 promoter, where ErbB-2 acts as
a Stat3 coativator.20 The proximal 1-kb cyclin D1 promoter lacks
ErbB-2 binding sites (HER2-associated sequences, HAS). Here, we
found that HRGβ1 induced cyclin D1 protein and mRNA
expressions in BC cells (Figures 5a and b and Supplementary
Figure S4a). Inhibition of ErbB-2 (AG825) and Stat3 (Jak inhibitor I,
Proietti et al.11) activity or knockdown of their expressions
abrogated HRGβ1 effects (Figures 5b and c and Supplementary
Figure S4b). These findings identify Stat3 as a novel player in
HRGβ1 modulation of cyclin D1 expression in BC. Chromatin
immunoprecipitation (ChIP) and sequential ChIP assays in C4HD
and T47D cells using primers spanning GAS sites in the mouse and
human cyclin D1 promoters, respectively, showed that HRGβ1
induces Stat3, ErbB-2 and ErbB-3 simultaneous binding to the said
region (Figures 5d and e). These findings identify the first nuclear
function of the ErbB-2/ErbB-3 dimer recruited along with Stat3 at
the GAS sites of the cyclin D1 promoter. This transcriptional
complex was also assembled under basal and HRGβ1-induced
conditions in BT-474 and JIMT-1 cells. Basal levels of corecruitment
of all three proteins were higher in JIMT-1 cells than in BT-474
(Figure 5f). Figure 5g shows HRGβ1 stimulation of cyclin D1
protein expression.
Figure 2. Comparison between hErbB-2ΔNLS and Ttzm effects in ErbB activation and BC growth. (a) Cells were transfected with the empty
pcDNA3.1 vector and treated with HRGβ1, Ttzm or pretreated with Ttzm before HRGβ1 stimulation. ErbB-2 (red) was localized by IF and
confocal microscopy. Nuclei were stained with 40,6-diamidino-2-phenylindole (DAPI) (blue). (b) Quantitative analysis of ErbB-2 subcellular
localization in confocal images of cells treated or untreated with HRGβ1 from panel (a). Fluorescence intensity ratio of MErbB-2 vs NErbB-2 was
calculated for 50 cells from each group. Data are presented as mean± s.d. (c) Effect of hErbB-2ΔNLS on ErbB-2 nuclear migration. BT-474 cells
were transfected with hErbB-2ΔNLS and treated with HRGβ1 or remained untreated. GFP from hErbB-2ΔNLS vector was visualized by direct
fluorescence imaging (green), and total ErbB-2 (red) was localized by IF. Solid arrows: Cells transfected with hErbB-2ΔNLS; dashed arrows: wild-
type cells that did not uptake the hErbB-2ΔNLS mutant. Nuclei were stained with DAPI (blue). (d) Inhibition of ErbB-2 nuclear localization
abolishes basal and HRGβ1-induced in vitro proliferation. Cells were transfected with hErbB-2ΔNLS or pcDNA3.1 vector. When indicated, cells
were pretreated with Ttzm and were then treated with HRGβ1 or remained untreated. Incorporation of [3H]thymidine was used as a measure
of DNA synthesis. Data are presented as mean± s.d. For c and e vs a: Po0.01; b vs a, d vs c and f vs b and d: Po0.001. (e) Effects of
hErbB-2ΔNLS on ErbB signaling. Cells were transfected as in (d) and were treated with HRGβ1, or were pretreated with Ttzm before HRGβ1
stimulation. WB analyses were performed with the indicated phospho (p) antibodies, and filters were reprobed with the respective total
antibody. (f) Protein extracts from SK-BR-3 cells were immunoprecipitated (IP) with ErbB-2 and analyzed by WB with ErbB-3 antibodies. As
control for the specificity of the protein interaction, lysates were IP with rabbit IgG. Total cell lysates were blotted in parallel. The experiments
shown in (a–f) are representative of a total of three.
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Figure 3. Inhibition of ErbB-2 nuclear localization blocks proliferation in Ttzm-resistant BC. (a) Cells transfected with pcDNA3.1 (left) or
hErbB-2ΔNLS (right) vectors were treated as indicated. ErbB-2 (red) and GFP-tagged-hErbB-2ΔNLS (green) were localized as in Figure 2. Solid
arrows: hErbB-2ΔNLS-transfected cells; dashed arrows: wild-type cells that did not uptake the hErbB-2ΔNLS mutant. Nuclei were stained with
40,6-diamidino-2-phenylindole (DAPI) (blue). (b–d) Quantitative analysis of ErbB-2 subcellular localization. Fluorescence intensities of MErbB-2
and NErbB-2 were quantified in 50 cells from each group and are plotted as the ratio of MErbB-2/NErbB-2 (b), the percentage of MErbB-2 (c) or
the percentage of NErbB-2 (d) (mean± s.d.). For # vs *: Po0.001. For b–e vs a, c–e vs b, and d vs c: Po0.001. For c and d vs e: Po0.05.
(e) Blockade of NErbB-2 localization inhibits in vitro growth. Cells were transfected and treated as indicated. Proliferation and data were
analyzed as in Figure 2. For b and c vs a, and d vs b: Po0.001. (f and g) Effect of hErbB-2ΔNLS on ErbB signaling. Cells were transfected and
treated as in (e). WB analysis (f) and immunoprecipitation analysis (g) were performed as in Figure 2. (h) Cell proliferation in intrinsic and
acquired Ttzm-resistant cells was evaluated by [3H]thymidine incorporation or cell count. Data are presented as in (e). For b and c vs a, and d
vs b: Po0.001. Experiments in (a–h) were repeated three times, with similar results. (i) hErbB-2ΔNLS blocks in vivo growth. Left panel: Cells
were inoculated subcutaneously in mice. When JIMT-1 tumors reached 40mm3, animals were divided into three groups and injected with
Ttzm, IgG or remained untreated. JIMT-1-hErbB-2ΔNLS-injected mice developed tumors with a latency of 40 days. Each point represents the
mean tumor volume± s.e.m. Right panel: Decrease in tumor mass. (j) Tumor growth. aGrowth rates were calculated as in Figure 1. Volume,
percentage of growth inhibition and delay in tumor growth from the different groups with respect to tumors from JIMT-1 cells were
calculated at day 64. # vs *: Po0.001. bWith respect to JIMT-1 cells, Po0.001 (see Supplementary Figure S2).
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Disruption of the Stat3/ErbB-2/ErbB-3 nuclear complex is the
differential molecular signature underlying hErbB-2ΔNLS growth
inhibitory effects in Ttzm-resistant cells
As we found that the signaling activated after Ttzm treatment of
JIMT-1 cells was the same as after transfection with the
hErbB-2ΔNLS (Figures 3f and g), we compared Ttzm and
hErbB-2ΔNLS effects on the assembly of the Stat3/ErbB-2/ErbB-3
nuclear complex. Ttzm was unable to block basal and HRGβ1-
induced ErbB-2 and ErbB-3 recruitment to the GAS sites at the
cyclin D1 promoter (Figure 6a). Contrastingly, ErbB-2 was not
recruited to this site in cells transfected with the hErbB-2ΔNLS in
basal or HRGβ1-stimulated conditions (Figure 6a), because of its
function as DN inhibitor of endogenous ErbB-2 nuclear localization.
In the absence of ErbB-2 recruitment, neither was ErbB-3 loaded at
Figure 3. Continued.
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Figure 4. ErbB-2, ErbB-3, Stat3 and HRGβ1 colocalize and physically associate in the nucleus. (a) HRGβ1 induces ErbB-2, ErbB-3 and Stat3
nuclear migration. Cells were treated as indicated. Nuclear and cytosolic protein extracts were analyzed by WB with phospho (p) antibodies
and reprobed with total antibodies. pErbB-2 blots were reprobed with ErbB-2 carboxyl (C)- or amino (N)-terminal antibodies as indicated. For
ErbB-2, total lysates were blotted. Histone H3 and β-tubulin were used to control cellular fractionation efficiency. (b, upper panel) ErbB-2
(green) and Stat3 (red) were localized by IF and confocal microscopy. Merged images show HRGβ1-induced ErbB-2/Stat3 nuclear colocalization
in yellow. Boxed areas are shown in detail in the inset. Nuclei were stained with 40,6-diamidino-2-phenylindole (DAPI) (blue). Lower panel:
Quantitative analysis of NErbB-2 levels in confocal images from upper panel. Fluorescence intensities of NErbB-2 were quantified and are
expressed as the percentage of NErbB-2 (mean± s.d., n= 50 from each group). (c) Nuclear extracts were immunoprecipitated (IP) with ErbB-2,
Stat3 or IgG (as control of specificity) antibodies, and analyzed by WB with the indicated p-antibodies. Membranes were reprobed with total
antibodies. Total cell lysates were blotted in parallel. (d and e) ErbB-2 (red) and ErbB-3 or HRG (green) were localized by IF; data are shown as
detailed in (b). Merged images show HRGβ1-induced ErbB-2/ErbB-3 (d) or ErbB-2/HRG (e) nuclear colocalization in yellow. Lower panel in (d)
shows quantitative analysis of NErbB-3 levels in confocal images. (f) Nuclear extracts were IP with ErbB-2, ErbB-3 or IgG antibodies, and
analyzed by WB with the indicated antibodies. Total lysates were blotted in parallel. (g and h) ErbB-2, Stat3 and ErbB-3 were localized by IF in
BT-474 and JIMT-1 cells; data are shown as in (b and d), respectively. (i) Effect of hErbB-2ΔNLS on ErbB-3 nuclear migration. hErbB-2ΔNLS-
transfected cells were treated with HRGβ1. GFP from hErbB-2ΔNLS was visualized by direct fluorescence imaging (green) and ErbB-3 (red) by
IF. Solid arrows: hErbB-2ΔNLS-transfected cells; dashed arrows: wild-type cells that did not uptake the hErbB-2ΔNLS mutant. Experiments in
(a–i) were repeated at least three times, with similar results (see Supplementary Figure S3).
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the promoter (Figure 6a), consistent with hErbB-2ΔNLS ability to
block ErbB-3 nuclear migration. Our study of the local chromatin
architecture revealed that CBP, a coactivator with histone
acetyltransferase activity, was recruited to the GAS site under
basal conditions, and that HRGβ1 further stimulated its recruit-
ment. Accordingly, basal levels of histone H3 acetylation were
found, which were enhanced by HRGβ1 treatment (Figure 6a).
Ttzm did not affect CBP recruitment or histone H3 acetylation
levels. On the contrary, neither recruitment of CBP nor modifica-
tion of histone H3 acetylation levels were observed in cells
transfected with hErbB-2ΔNLS (Figure 6a). While Ttzm was unable
to abolish HRGβ1-induced cyclin D1 protein and mRNA expres-
sion, transfer of hErbB-2ΔNLS blocked the said HRGβ1 effects
(Figures 6b and c). These findings demonstrate that hErbB-2ΔNLS
Figure 4. Continued.
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Figure 5. HRGβ1 induces the assembly of a Stat3/ErbB-2/ErbB-3 transcriptional complex at the cyclin D1 promoter in both Ttzm-sensitive
and -resistant BC cells. (a) Cyclin D1 expression was analyzed by WB. (b) Cells were transfected with ErbB-2, Stat3 and control siRNAs and
were treated with HRGβ1. Cyclin D1 mRNA expression levels were determined by RT–qPCR. Fold change of mRNA levels upon HRGβ1
treatment was calculated by normalizing the absolute levels of cyclin D1 mRNA to GAPDH levels, used as an internal control, setting the
value of untreated cells as 1. Data are presented as mean± s.e.m. For b vs a: Po0.001. (c, upper panel) Cells were preincubated with the
indicated pharmacologic inhibitors or transfected as in (b) and were treated with HRGβ1. Cyclin D1 levels were studied by WB. Lower
panel: control of inhibition of Stat3 expression by siRNAs. Experiments in (a) to (c) were repeated three times, with similar results. (d) HRGβ1
induces in vivo binding of Stat3, ErbB-2 and ErbB-3 to the cyclin D1 promoter. Protein recruitment to cyclin D1 promoter was analyzed by ChIP
in cells treated with HRGβ1. Immunoprecipitated DNA was amplified by qPCR using primers (red arrows) flanking the GAS sites (upper
diagrams). Amounts of immunoprecipitated DNA were normalized to inputs and are reported relative to the amount obtained by IgG
immunoprecipitation, used as a negative control, which was set to 1. Data are expressed as n-fold chromatin enrichment over IgG
immunoprecipitation. For b vs a: Po0.001. (e) Sequential ChIP. Chromatins were first immunoprecipitated with Stat3 or ErbB-2 antibodies and
were reimmunoprecipitated using ErbB-2 or ErbB-3 antibodies. qPCR and data analysis were performed as in (d). For b vs a: Po0.001.
(f) Sequential ChIP assays were performed in BT-474 and JIMT-1 cells as in (e). Immunoprecipitated DNA was amplified by qPCR using primers
flanking the GAS site at − 984 shown in (d). Results in (d–f) are mean± s.e.m. from three independent experiments. (g) Cyclin D1 expression
was analyzed by WB. As control, T47D cells were blotted in parallel. The experiment shown was repeated three times with similar results (see
Supplementary Figure S4).
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inhibitory effects on Ttzm-resistant JIMT-1 cells lies in the
disruption of the Stat3/ErbB-2/ErbB-3 nuclear complex driving
cyclin D1 expression.
ErbB-2 and Stat3 nuclear coexpression is associated with poor
clinical outcome
We explored the clinical significance of ErbB-2 and Stat3 nuclear
coexpression in tissue microarrays from 42 MErbB-2-
overexpressing primary breast tumors. The clinical and patholo-
gical characteristics of these specimens are shown in
Supplementary Table S1. In this cohort, 22 patients belong to
the luminal B-like, HER2-positive (estrogen receptor (ER)- and/or
progesterone receptor (PR)-positive, MErbB-2-overexpressed) BC
subtype and 19 to the HER2-positive, non-luminal (ER- and PR-
negative, MErbB-2-overexpressed) subtype, according to the
surrogate definitions of intrinsic BC subtypes48 (Supplementary
Table S1). Here, MErbB-2 was studied by immunohistochemistry
and immunofluorescence (IF)49,50 and NErbB-2 by IF, and scored as
we reported.49 NStat3 was studied by IF20 and scored as NErbB-
2,49 considering the percentage of positive cells and staining
intensity (Supplementary Figure S5 details scoring). Scores of 2+
and 3+ were considered positive for NErbB-2,49 and of 1+ to 3+,
positive for NStat351 (Supplementary Figure S5). Among 11 tumors
expressing NErbB-2, nine also coexpressed NStat3 (81%, 95%
confidence interval = 48–97). Representative samples are shown in
Figure 7a. NErbB-2/NStat3 coexpression was significantly asso-
ciated with higher clinical stage in our total cohort of MErbB-2-
overexpressing tumors (Supplementary Table S2). No significant
correlation between the BC subtype and NErbB-2/NStat3 coex-
pression was found (Supplementary Table S2). Kaplan–Meier
analysis revealed that coexpression correlated with lower overall
survival (Figure 7b). These results validate in the clinic our findings
on the key role of the NErbB-2/NStat3 complex as driver of
proliferation in ErbB-2-positive BC.
DISCUSSION
Our findings challenge the paradigm of anti-ErbB-2 drug design,
revealing that blockade of NErbB-2 presence abrogates growth of
BC sensitive and resistant to Ttzm. We found that ErbB-2 assembly
of a transcriptional complex with ErbB-3 and Stat3 at the cyclin D1
promoter modulates basal and HRGβ1-induced BC growth. Our
results highlight nuclear ErbB-2 as the major driver of proliferation
in Ttzm-resistant BC and demonstrate that Ttzm inability to
disrupt the Stat3/ErbB-2/ErbB-3 transcriptional complex and cyclin
D1 expression underlies its failure to inhibit BC growth.
Increasingly, strong evidence, including ours, revealed nuclear
presence and function of ErbB-2, as well as of other ErbB family
members and their ligands in BC.6,19–24 We also identified NErbB-2
positivity as an independent prognostic factor of worse overall
survival in patients with MErbB-2 overexpression.49 In spite of these
Figure 6. Disruption of the Stat3/ErbB-2/ErbB-3 nuclear complex is the differential molecular signature underlying hErbB-2ΔNLS growth
inhibitory effects in Ttzm-resistant cells. (a) The hErbB-2ΔNLS abolishes the assembly of the ErbB-2/ErbB-3 complex at the cyclin D1 promoter.
Cells were transfected with the hErbB-2ΔNLS or pcDNA3.1 vector. When indicated, cells were pretreated with Ttzm and were then treated with
HRGβ1 or remained untreated. Recruitment of ErbB-2, ErbB-3 and CBP, and H3 acetylation levels (H3Ac) at the cyclin D1 promoter was
analyzed by ChIP. IgG immunoprecipitation was used as a negative control. Immunoprecipitated DNA was amplified by qPCR using primers
flanking the GAS site at position − 984, shown in Figure 5. Amounts of immunoprecipitated DNA were normalized to inputs and are reported
relative to the amount obtained by IgG immunoprecipitation, which was set to 1. For b and c vs a, and d vs b: Po0.001. Data represent the
means of data from three independent experiments± s.e.m. (b) Cyclin D1 protein levels in cells treated as described in (a) were analyzed by
WB as in Figure 5. (c) Cyclin D1 mRNA expression levels in cells treated as in (a) were determined by RT–qPCR. Data analysis was performed as
in Figure 5. Data are presented as mean± s.e.m. For b and c vs a, and d vs b: Po0.001. Experiments in (b) and (c) were repeated three times,
with similar results.
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Figure 7. ErbB-2 and Stat3 nuclear coexpression is associated with poor clinical outcome. (a) NErbB-2 and NStat3 coexpression in tumor
samples. Upper panel: NErbB-2 and NStat3 levels were evaluated by IF and scored as described in Results. Shown are examples of tumors
showing positive NErbB-2/NStat3 coexpression. Nuclei were stained with 40,6-diamidino-2-phenylindole (DAPI). Lower panel: A schematic
overview of the tissue microarrays (TMAs) and a summary of the IF results are shown. Positive specimens are shown in red and negative
specimens, in blue. (b) Kaplan–Meier survival analysis and log-rank test were performed to correlate NErbB-2/NStat3 coexpression with overall
patient survival in MErbB-2-overexpressing patients. (c) Model of Ttzm and hErbB-2ΔNLS action. Ttzm-sensitive cells display higher levels of
MErbB-2 than of NErbB-2 and their proliferation is driven by signaling (e.g. PI3K/AKT) and nuclear (e.g. Stat3/ErbB-2/ErbB-3 transcriptional
complex at cyclin D1 promoter) ErbB-2 actions, both hierarchically equal. Inhibition of signaling with Ttzm or of nuclear action with
hErbB-2ΔNLS blocks proliferation. Ttzm-resistant cells display high levels of NErbB-2, which indeed may be higher than those of MErbB-2.
NErbB-2 role on proliferation is stronger than that of MErbB-2. Therefore, inhibition of NErbB-2 effect with hErbB-2ΔNLS blocks BC growth
even in the presence of signaling pathways' activation (see Supplementary Figure S5 and Supplementary Tables S1 and S2).
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experimental and clinical findings, the current anti-ErbB-2 therapy
with Ttzm targets only MErbB-2. De novo or acquired resistance to
Ttzm is still a major clinical issue.52,53 Where Ttzm failed, other
therapies have proved efficient, like pertuzumab, which inhibits
ligand-induced ErbB-2/ErbB-3 heterodimerization,29,54 and the
kinase inhibitor lapatinib.55,56 Yet again, both target only MErbB-2.
Our BC models display multiple mechanisms of Ttzm failure.
HRG induces the assembly of ErbB-2/ErbB-3 dimers insensitive to
Ttzm disruption in BT-474 and SK-BR-3 cells.29,34 Owing to either
activating mutations in PIK3CA or decreased levels of the PTEN
phosphatase, PI3K/AKT activation is a mechanism of resistance26,27
present in all Ttzm-unresponsive lines we studied.41,57 HCC1419
cells express a constitutively active truncated ErbB-2, which
correlates with lack of Ttzm effect.41,58 Increased EGF-R expression
and phosphorylation and high levels of ErbB ligands have been
identified as a mechanism of acquired Ttzm resistance in BT-474
cells.42 We here revealed increased NErbB-2 expression as a novel
common feature underlying intrinsic and acquired Ttzm
resistance. Most of the intrinsic Ttzm-resistant cells we studied
showed higher levels of NErbB-2 than of MErbB-2. Also, HRGβ1-
conferred resistance correlates with an inversion of MErbB-2/
NErbB-2 ratios or with a striking increase in NErbB-2 levels.
Similarly, acquired resistance in BT-474 cells resulted in higher
NErbB-2 content than that in their sensitive counterparts. As
regards the response to anti-ErbB-2 therapies, our results suggest
that the concept of ErbB-2 overexpression should be extended to
include NErbB-2 levels.
In all Ttzm-responsive and -resistant human BC lines studied, we
found basal nuclear ErbB-2, ErbB-3 and Stat3, as well as ErbB-2/
ErbB-3 and ErbB-2/Stat3 nuclear colocalization, which was
increased by HRGβ1. Basal MErbB-2/MErbB-3 dimers were more
numerous in sensitive cells than in resistant cells, and conversely,
nuclear dimers were more abundant in resistant cells, suggesting
a role of nuclear ErbB dimers in Ttzm response. Indeed, our
mechanistic studies revealed basal and HRGβ1-induced assembly
of a Stat3/ErbB-2/ErbB-3 transcriptional complex at the GAS sites
of the cyclin D1 promoter, where ErbB-2 and ErbB-3 act as Stat3
cofactors. Although MErbB-2 and HRG involvement in cyclin D1
expression via signaling pathways has been found,59–62 this is the
first report of a nuclear function of the ErbB-2/ErbB-3 dimer,
resulting in the regulation of cyclin D1 expression. Nuclear ErbB-3
was detected in mammary epithelial and BC cells.6,23,24,63 Recently,
the full-length and a 80 kDa ErbB-3 variant were found recruited to
cyclin D1 promoter regions with multiple GAS sites, including the
one studied here,20,64 and to induce said regions' transcriptional
activity in BC cells.24,65 ErbB-3-response elements have not yet
been characterized, which prevents the determination of whether
ErbB-3 is bound directly to DNA. Our findings raise the possibility
that in these reports ErbB-3 was loaded as cofactor of Stat3 at said
promoter regions enriched in GAS sites. The presence of several
HRG isoforms in the nucleus of BC cells and primary tumors has
already been reported.21,22 However, the biologic function of
nuclear HRG in BC remains poorly known. While nuclear HRGβ1
appears to be involved in the induction of gene expression, HRGα
functions as a transrepressor in luciferase reporter assays.21,66 Our
findings revealed that at the nuclear compartment, HRGβ1
remains bound to ErbB-3, its cognate receptor, and assembles a
transcriptional complex with ErbB-2 and Stat3, which modulates
cyclin D1 expression and BC growth.
In line with NErbB-2 central role in BC growth, we found
that inhibition of ErbB-2 nuclear localization by transfer of
hErbB-2ΔNLS blocks in vitro and in vivo HRGβ1-induced growth
of a MErbB-2-overexpressing BC mouse model, basal and HRGβ1-
stimulated in vitro growth of ErbB-2-amplified human BC cells,
both Ttzm-sensitive and -resistant, and proliferation of a
preclinical model of Ttzm-resistant BC. Our comparative studies
on hErbB-2ΔNLS and Ttzm effects showed that inhibition of ErbB-2
nuclear localization abolishes basal and HRGβ1-stimulated growth
of ErbB-2-positive BC in the presence of ErbB-2/ErbB-3 dimers,
ErbB-3 phosphorylation and PI3K/AKT pathway activation, condi-
tions where Ttzm is inefficient.27,29,34,38 On the other hand, Ttzm
was unable to block basal and HRGβ1-stimulated NErbB-2
presence. Disruption of the Stat3/ErbB-2/ErbB-3 complex govern-
ing cyclin D1 expression was the differential molecular signature
underlying growth inhibitory effects of hErbB-2ΔNLS in Ttzm-
resistant BC. Our results are consistent with a model (Figure 7c)
where, in cells displaying higher levels of MErbB-2 than of
NErbB-2, proliferation is driven by signaling and nuclear ErbB
actions, both hierarchically equal. Inhibition of signaling with Ttzm
or of nuclear actions with hErbB-2ΔNLS would block proliferation.
Contrastingly, in BC cells displaying high levels of NErbB-2, which
may be basally higher than those of MErbB-2 or may be increased
by HRGβ1 treatment, NErbB-2 role on proliferation is stronger than
that of MErbB-2. Thus, inhibition of NErbB-2 action would be the
appropriate strategy to block proliferation (Figure 7c).
Our clinical findings showed that NErbB-2/NStat3 interaction
correlates with poor clinical outcome in MErbB-2-overexpressing
BC. Interestingly, the said interaction is not restricted to the HER2-
positive (non-luminal) BC subtype, but occurs also in luminal B-like
HER2-positive tumors. This finding indicates that NErbB-2/NStat3
coexpression may serve as a new biomarker of prognosis in all
breast tumors overexpressing MErbB-2. Our present results in
experimental models and in the clinic reveal the blockade of




BALB/c mice studies were conducted as outlined in the NIH Guide for the
Care and Use of Laboratory Animals and were approved by the IBYME
Animal Research Committee.20
Antibodies and reagents
Antibodies and reagents are listed under Supplementary Materials and
methods.
Cell lines, treatments and proliferation assays
C4HD epithelial cells from the model of mammary carcinogenesis induced
by medroxyprogesterone acetate in mice overexpress ErbB-2 and ErbB-3,
exhibit low ErbB-4 levels and lack EGF-R expression.9 These cells also
display high levels of ER and PR.9 BT-474, SK-BR-3 and T47D cells were
obtained from American Type Culture Collection (Manassas, VA, USA), and
JIMT-1 cells were from the German Tissue Repository DSMZ (Braunschweig,
Germany). MDA-MB-453, HCC1569 and HCC1419 were a gift from DJ
Slamon (University of California, Los Angeles, CA, USA). BT-474HR clone,
selected for its resistance to Ttzm, was obtained following the previously
described protocol.42 Primary cultures of epithelial cells from C4HD tumors
were performed as described.9 BT-474, SK-BR-3, BT-474HR and T47D cells
were cultured as described previously.11,20,67,68 JIMT-1 cells were main-
tained in DMEM-F12 (Dulbecco's modified Eagle's medium/nutrient
mixture F12) supplemented with 10% fetal calf serum. MDA-MB-453,
HCC1569 and HCC1419 cells were cultured as described by DJ Slamon.41
All cell types were starved in 0.1% charcoalized fetal calf serum for 48 h
before stimulation with HRGβ1 (40 ng/ml), or were pretreated with Ttzm
(10 μg/ml), AG825 (10 or 100 μM) or Jak inhibitor I (1 μM) for 90min before
HRGβ1 stimulation. In experiments assessing the effects of mutant ErbB-2
(hErbB-2ΔNLS), cells were transfected as described with the corresponding
plasmid or pcDNA3.1 empty plasmid for 24 h before HRGβ1 treatment.20
Proliferation was evaluated by [3H]thymidine incorporation assay or cell
count, and cell cycle distribution was evaluated by flow cytometry.20,69
Western blot analysis and immunoprecipitation assays
Sodium dodecyl sulfate–polyacrylamide gel electrophoresis and immuno-
blots were performed as described.20 The association among ErbB-2,
ErbB-3 and Stat3 was studied by co-immunoprecipitation experiments
using 500 μg of nuclear or total cell lysates as described.20 A detailed
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description of western blot (WB) analysis is provided in Supplementary
Materials and methods.
Plasmids and transient transfections
Plasmids and siRNA sequences are detailed under Supplementary
Materials and methods. Fugene HD transfection technique (Roche
Biochemicals, Indianapolis, IN, USA) was performed as described.20
Transfection of siRNA duplexes was performed for 3 days by using
DharmaFECT transfection reagent (Dharmacon, Lafayette, CO, USA)
according to the manufacturer’s instructions. For reconstitution experi-
ments, co-transfection of 25 nM ErbB-2 siRNA with 2 μg expression vectors
was performed using DharmaFECT Duo transfection reagent (Dharmacon).
IF and confocal microscopy in cell cultures
Techniques were performed as we already described.20 Cells were
analyzed using a Nikon Eclipse E800 confocal laser microscopy system.20
A detailed description of antibodies used and of quantitative analysis of
confocal images is provided in Supplementary Materials and methods.
ChIP and sequential ChIP assays
ChIP and sequential ChIP assays were performed as we described.20
Primers used are listed in Supplementary Materials and methods.
RNA preparation and real-time quantitative RT–PCR
RNA was obtained and cyclin D1 mRNA levels were detected as we
described.20 Primers used are listed in Supplementary Materials and
methods.
Preclinical models
C4HD cells were transfected with pcDNA3.1 or hErbB-2ΔNLS vectors and
106 cells from each group (n= 6) were inoculated subcutaneously into NIH
(S) nude mice (La Plata University, La Plata, Buenos Aires, Argentina)
treated with a 5 μg HRGβ1 slow-release pellet as described under
Supplementary Materials and methods. Tumor volume, growth rate and
growth delay were determined as described.20 Comparison of tumor
volumes between different groups was carried out by analysis of variance
followed by Tukey’s test. Linear regression analysis was performed on
tumor growth curves, and the slopes were compared using analysis of
variance followed by a parallelism test to evaluate the statistical
significance of differences.
JIMT-1 cells were transfected with expression vectors and 4× 106 cells
from each group were inoculated subcutaneously into NIH(S) nude mice.
When tumors developed from pcDNA3.1-transfected cells reached 40
mm3, animals were divided into three groups (n= 8) and injected with
Ttzm (20mg/kg, intraperitoneally), or with human IgG as control (20mg/
kg, intraperitoneally) two times a week, or remained untreated. Tumor
volume, growth rate and growth delay were determined as explained.
Patients and tissue microarrays
We selected 42 MErbB-2-overexpressing paraffin-embedded tissue sam-
ples from a cohort of archived invasive breast carcinomas from the files of
the Histopathology Department of Temuco Hospital, Chile, from 1998 to
2006.49 This study was conducted with the approval of the Institutional
Review Board on Human Research of Universidad de La Frontera. Details of
informed consents, pretreatment staging of patients, treatments, tissue
microarray construction and IF analysis are provided in Supplementary
Materials and methods.
Statistics
Analyses were performed using STATA version 11 software (Stata Corp.,
College Station, TX, USA). Correlations between categorical variables were
performed using Fisher’s exact test. Cumulative overall survival probabil-
ities were calculated according to the Kaplan–Meier method, and statistical
significance was analyzed by log-rank test. All the tests of statistical
significance were two-sided. P-values o0.05 were regarded as statistically
significant.
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